Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 27;2(1):ltac002. doi: 10.1093/immadv/ltac002

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Immunology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Figure 4. — Serum and urine gold concentration following administration of C19-A3 GNP. (a) Serum gold concentration; (b) urine gold concentration. Blood and urine samples for measurement of gold concentration were taken at baseline (week 0), one day after 1st dose (week 0 + 1 day) and one day after 3rd dose (week 8 + 1 day). Detection limit was 0.2 ng/ml and quantitation limit 0.6 ng/ml. Levels below detection and quantitation limit are presented as zero on the graph. Each line represents an individual participant with an assigned study number as shown in the legend.